INTERNATIONAL JOURNAL OF ONCOLOGY 44: 319-326, 2014
Female gender may predict response to FOLFIRINOX
in patients with unresectable pancreatic cancer:
A single institution retrospective review
1* 1* 1 1
FLORIAN HOHLA , GEORG HOPFINGER , FRANZ ROMEDER , GABRIEL RINNERTHALER ,
1 2 3
ANGELIKA BEZAN , STEFAN STÄTTNER , CORNELIA HAUSER-KRONBERGER ,
4 1
HANNO ULMER and RICHARD GREIL
1
Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and
Infectious Diseases, Oncologic Center, Center for Clinical Cancer and Immunology Trials, Laboratory of Immunological and
2 3
Molecular Cancer Research, Surgical Department, Department of Pathology, Paracelsus Medical University of Salzburg,
4
A-5020 Salzburg; Department of Medical Statistics, Informatics and Health Economics,
Innsbruck Medical University, A-6020 Innsbruck, Austria
Received August 25, 2013; Accepted October 15, 2013
DOI: 10.3892/ijo.2013.2176
Abstract. FOLFIRINOX is a highly active regimen for the female patients when primarily treated compared to treatment
treatment of patients with unresectable pancreatic cancer. after surgical resection and relapse (77.8%, p=0.057). For all
However, treatment with FOLFIRINOX is associated with patients median PFS was 3.5 months (95% CI, 2.7-4.3 months)
relevant toxicity and predictors for response to therapy are and median OS was 13 months (95% CI, 9.4-16.6 months).
warranted. We retrospectively analyzed 49 patients with Female patients showed a tendency towards a longer median
unresectable pancreatic cancer treated with FOLFIRINOX in PFS (5.0 months, 95% CI, 3.6-6.4 months) compared to males
order to evaluate a possible predictive role of clinical param- (3.0 months, 95% CI, 2.4-3.6 months) (p=0.099). Serum
eters and tumor characteristics for response to chemotherapy. levels of CA19.9 and CEA were significantly higher in female
Tumor samples were characterized histopathologically before patients compared to male patients (p=0.037, p=0.05). Tumors
treatment and expression of p53 and Ki67 was analyzed using of patients with response to FOLFIRINOX showed a higher
automated immunohistochemistry. Overall survival (OS) and expression level of p53 and Ki67 as well as higher serum levels
progression-free survivall (PFS) were estimated by the Kaplan- of CA19.9 compared to non-responders, which was statistically
Meier method. The overall objective response rate was 55.1%, the not significant. Our study indicates that female gender is a posi-
disease control rate was 70.6%. Female gender was associated tive predictor for therapy response to FOLFIRINOX in patients
with a significantly higher disease control rate of 91.7 compared with unresectable pancreatic cancer. Female gender in turn was
to 48.0% in male patients (p=0.001) which reached 100% in associated with increased levels of tumor markers CEA and
CA19.9 and patients with higher serum levels of CA19.9 were
more responsive to FOLFIRINOX.
Correspondence to: Dr Florian Hohla, Third Medical Department Introduction
with Hematology, Medical Oncology, Hemostaseology, Rheumatology
and Infectious Diseases, Oncologic Center, Center for Clinical Cancer Pancreatic cancer is the fourth leading cause of cancer-related
and Immunology Trials, Laboratory of Immunological and Molecular
death in men and women (1). Up to 85% of patients are diag-
Cancer Research, Paracelsus Medical University of Salzburg, Müllner
nosed at an advanced stage when the tumor is unresectable
Hauptstrasse 48, A-5020 Salzburg, Austria
because of infiltration of local arteries or distant metastasis
E-mail: f.hohla@salk.at
(2). Gemcitabine has been the standard of care for the treat-
*Contributed equally ment of advanced pancreatic cancer based on a randomized
trial showing an improvement in the one-year survival with
Abbreviations: CTX, chemotherapy; BMI, body mass index; gemcitabine compared to 5-fluorouracil (5-FU) (3). Although
PR, partial remission; SD, stable disease; PD, progressive disease; well-tolerated, the efficacy of gemcitabine is modest, with
APC, advanced pancreatic cancer; CEA, carcinoembryogenic antigen; reported response rates (RR) of 10% and median survival of
CA19.9, carboanhydrase 19.9 less than 7 months (3). The combination of gemcitabine with
a variety of cytotoxic and targeted agents has generally shown
Key words: pancreatic cancer, FOLFIRINOX, chemotherapy, female
no significant survival advantage as compared to gemcitabine
gender, predictive markers, p53, Ki67
alone (4). Some studies have suggested a significant benefit
in overall survival (OS) and progression-free survival (PFS)
320 HOHLA et al: PREDICTIVE MARKERS FOR THERAPY RESPONSE TO FOLFIRINOX
associated with gemcitabine-based cytotoxic combinations in monoclonal mouse anti-human Ki67 (clone MIB-1, Dako,
patients with good performance status (5,6). An impressive effi- Glostrup, Denmark) at a working dilution of 1:500 and
cacy and longer median OS of 10.2 months was first reported monoclonal mouse anti-human p53 (clone DO-7, Dako) at a
in a phase II study in patients with advanced pancreatic cancer working dilution of 1:200 on routinely formalin-fixed paraffin
under treatment with the combination regimen FOLFIRINOX embedded (FFPE) tissue, using a standardized automated plat-
(oxaliplatin, irinotecan, 5-FU and leucovorin) (7). Subsequently, form (AutostainerPlus, Dako) in combination with Envision
FOLFIRINOX was compared to gemcitabine in a randomized polymer detection system (Dako). Archival FFPE sections
phase III trial in patients with advanced pancreatic cancer (8). (3 µm) were deparaffinized in combination with heat-induced
This study confirmed statistically significant and clinically rele- epitope retrieval (HIER) at 98˚C for 40 min in antigen
vant improvements in OS (11.1 vs. 6.8 months), PFS (6.4 vs. 3.3 retrieval buffer pH 9.0 (Dako) in a PT Link™-module (Dako).
months) and RR (31.6 vs. 9.4%) with FOLFIRINOX compared Endogenous peroxidase blocking was carried out for 10 min
to gemcitabine alone. Because of significant higher grade 3 and with 3% H O in absolute methanol and normal serum was
2 2
4 toxicities (mostly neutropenia, diarrhea, febrile neutropenia, applied. Primary antibodies and detection reagents were incu-
thrombocytopenia, sensory neuropathy) with FOLFIRINOX bated at RT for 30 min and after several washes detection was
and the limited survival time of patients with advanced pancre- performed using EnvisionFlex™ detection system, followed by
atic cancer, biomarkers allowing a better patient selection are chromogenic visualisation with diaminobenzidine (DAB) for
required. Therefore, the aim of our study was to assess clinical 10 min. Nuclear counterstaining was performed with hema-
(age, body mass index, gender), histopathological [histology, toxylin. Assessment of Ki67 and p53 staining was performed
grading, tumor location, T-stage, levels of carboanhydrase 19.9 according to the recommendations of the International Ki67 in
(CA19.9) and carcinoembryogenic antigen (CEA), p53 and Breast Cancer working group (10). At least three high-power
Ki67 expression] parameters of patients with advanced pancre- (x40 objective) fields and clear hot spots were selected to
atic cancer treated with FOLFIRINOX and their association represent the spectrum of staining seen and 100 cancer cells
with response to treatment. were evaluated.
Materials and methods CA19.9 and CEA measurement. CA19.9 and CEA measure-
ments were carried out at a certified laboratory associated with
Study design and assessment of response. We conducted a the hospital by an electrochemiluminescence immunoassay
retrospective review of all patients with either primarily locally (Roche Diagnostics, Mannheim, Germany). The upper limit
advanced, metastatic or recurrent unresectable pancreatic normally used for CA19.9 was 37 U/ml and for CEA 3.5 µg/l.
cancer treated with FOLFIRINOX at our department between Serum levels of CA19.9 and CEA were measured before
October, 2010 and November, 2012. We evaluated patient and therapy and every second week during therapy.
tumor characteristics such as gender, age, age adapted body
mass index (BMI), performance status, T-stage according to Statistics. Baseline and clinicopathological characteristics were
the TNM classification, initial tumor localization (the head summarized as median and range for continuous variables and
vs. the body, tail or the papilla of the pancreas) and primary as absolute and relative frequencies for categorical variables.
metastases (hepatic, peritoneal, pulmonal) or localization of Comparisons in regard to gender and therapy response were
relapse (local vs. visceral metastasis) based on review of the either performed with the Kruskal-Wallis, the Mann-Whitney
patients' medical records. Response was assessed by review of U or the χ2 test. P-values <0.05 were considered to indicate
the patients imaging studies according to RECIST criteria as statistical significance. Tumor markers were correlated with
complete (CR), partial response (PR), stable disease (SD) or each other using Spearman rank correlation coefficient. A
progressive disease (PD) as well as by tumor marker response multivariate logistic regression model was performed to assess
of CA19.9 (9). Thus, a decrease or increase in CA19.9 by 50% the joint effect of gender, age and clinical variables such as
compared to baseline after treatment was classified as PR tumor stage, line of treatment (primary treatment vs. treatment
or PD, respectively. The objective response rate was defined in the relapsed stage) and biomarkers such as Ki67 and p53 on
as the percentage of patients with CR and PR. The disease the response rate. OS and PFS were estimated using the Kaplan-
control rate was defined as the percentage of patients with Meier method together with the log-rank test. As survival
CR, PR and SD (Table I). measures, median and 95% confidence intervals are given.
Treatment. Full dose FOLFIRINOX consisted of oxaliplatin Results
85 mg/m2 over 3 h, followed by irinotecan 180 mg/m2 over
90 min and leucovorin 400 mg/m2 over 2 h, followed by 5-FU Characteristics of the patients. Between October 2010 and
400 mg/m2 as a bolus and 2,400 mg/m2 as a 46 h continuous November 2012 a total of 52 patients with either locally
infusion. Dose modifications due to toxicity were made advanced non-metastatic (n=6), metastatic (n=31) or relapsed
according to the discretion of the treating physician. Treatment unresectable pancreatic cancer after initial resection (n=15)
was discontinued in case of unacceptable toxicity, progression were treated with FOLFIRINOX at our department (Fig. 1).
of disease or pursuit of alternative therapies including surgical Two patients discontinued CTX after the first application due
resection or radiotherapy for locally advanced disease (Fig. 1). to grade 3 toxicities (1 febrile neutropenia, 1 diarrhea) or cancer
related complications (1 patient with ileus) and therefore were
Immunohistochemistry. Immunohistochemical staining for excluded from our analysis. Thus, a total of 49 patients could
Ki67 and p53 protein was performed using the antibodies finally be included in our study. Demographic and tumor
INTERNATIONAL JOURNAL OF ONCOLOGY 44: 319-326, 2014 321
Table I. Demographic and baseline characteristics of all the and SD in 27 (55.1%) and 7 (14.3%) patients, respectively. There
patients. were no complete remissions (CR). Fifteen out of 49 patients
(30.6%) patients did not respond to a CTX with FOLFIRINOX
Characteristics and were classified as PD (Table III). When response rates were
analyzed according to gender, a significantly higher objective
Gender, no. (%)
response rate, defined as patients with either CR or PR, of 75 vs.
Male 24 (49)
36% (p=0.004) as well as a higher disease control rate defined
Female 25 (51)
as patients with either PR or SD of 91.7 vs. 48% (p=0.001) was
Age, years seen in female patients compared to male patients (Table III).
Median 62 The predictive effect of gender on the response rate remained
Range 42-76 statistically significant (p=0.041) in the multivariate logistic
BMI regression analysis adjusting for age, tumor stage, line of
Median 22.3 treatment, Ki67 and p53. Two female patients with metastatic
Range 17.2-34.8 disease as well as 2 male patients with locally advanced disease
were able to undergo resection (Fig. 1).
ECOG performance score 0, no. (%) 49 (100)
Histology, no. (%)
Efficacy of FOLFIRINOX in primarily treated and relapsed
Adenocarcinoma 42 (95.5)
pancreatic carcinomas. Disease control rates in the whole
Giant cell carcinoma 1 (2.3)
study population did not differ significantly when RRs were
Adenosquamous carcinoma 1 (2.3)
assessed in untreated patients compared to patients after
No histology 5 (10)
surgical resection and treatment in the relapsed stage (70.6 vs.
Grading 66.7%). However, when patients were analyzed according to
2 28 (65.1) gender and line of treatment, in women FOLFIRINOX caused
3 15 (34.9) a disease control rate of 100% in the first-line setting compared
Pancreatic tumor localization, no. (%) to 77.8% in the relapsed stage (p=0.057). Male patients showed
Head 24 (49.0) a significantly lower disease control rate of 47.4% after first-
Body 7 (14.3) line treatment than females (p=0.001). Their response rates
Tail 16 (32.7) in first-line and treatment in the relapsed stage (50%) did not
Papilla vateri 2 (4.1) differ (p=0.670) (Table IV).
T-stage
Progression-free and overall survival. Survival data are
2 3 (6.7)
shown in Table V and Fig. 2. For the entire cohort of patients
3 26 (57.8)
the median PFS was 3.5 months (95% CI, 2.7-4.3 months) with
4 16 (35.6)
a median OS of 13 months (95% CI, 9.4-16.6 months). Despite
Non-metastatic disease, no. (%) 6 (12.2)
significantly higher response rates, female patients showed
Metastatic disease, no. (%) 28 (57.1) only a tendency towards a longer median PFS of 5 months
Metastatic sites compared to 3 months in male patients (p=0.09) (Fig. 2A).
Liver 15 (53.6) The median OS did not significantly differ between female
Liver/peritoneum 8 (28.6) (15 months, 95% CI, 6.5-23.5 months) and male patients (12
Lung 4 (14.3) months, 95% CI, 9.7-14.3 months) (p=0.20) (Fig. 2B).
Liver/lung 4 (14.3)
Relapsed disease, no (%) 15 (30.6) Clinicopathological characteristics and their association
Locoregional 1 (6.7) with response to treatment with FOLFIRINOX. There was
Visceral (liver, lung, periteonal) 7 (46.7) no significant associations of either age, BMI, serum levels of
Locoregional and visceral 7 (46.7) CA19.9 and CEA or expression of p53 and Ki67 in pancreatic
tumors with response to FOLFIRINOX (Table VI). However,
ECOG, Eastern Cooperative Oncology Group; BMI, body mass index. tumors of patients with PR to FOLFIRINOX showed a tendency
towards a higher expression of Ki67 and p53 as well as higher
levels of CA19.9 compared to resistant tumors. In univariate
analysis CA19.9 levels were significantly associated with the
parameters were equally distributed between both genders expression of Ki67 (p=0.017, r=0.39) (data not shown).
(Table ΙΙ). Although female patients showed higher numbers
of metastatic tumors (15 vs. 13) and no locally advanced Discussion
non-metastatic tumors before treatment compared to males
(0 vs. 6 months) (p=0.095), they were characterized by signifi- Most patients with pancreatic cancer are either unresect-
cant higher levels of CA19.9 (p=0.037) and CEA (p=0.05). able at diagnosis or will suffer from a relapse after initial
surgery, resulting in a 5-year OS of 6% (11). The median OS
Efficacy of FOLFIRINOX in the whole study population and of patients with advanced or metastatic pancreatic cancer is
according to gender. Based on the imaging studies of the 6 months with most chemotherapeutic options (4). Treatment
patients as well as tumor marker response we confirmed a PR with FOLFIRINOX has offered a new option for patients with
322 HOHLA et al: PREDICTIVE MARKERS FOR THERAPY RESPONSE TO FOLFIRINOX
Table II. Demographic and baseline characteristics of female vs. male patients.
Characteristics Female (n=24) Male (n=25) P-value
Age, years
Median 61 63 0.603
Range 42-73 45-76
BMI
Median 22.3 22.9 0.379
Range 17.2-34.8 17.3-30-7
Level of carbohydrate antigen 19.9
Median 2494 185 0.037
Range 0-140241 0-32266
Level of carcinoembryogenic antigen
Median 10.4 5.7 0.05
Range 2-363 2-306
Level of Ki-67 positive cancer cells (%)
Median 30 20 0.457
Range 1-80 1-70
Level of mutant p53 cancer cells (%)
Median 30 1 0.147
Range 1-100 0-90
Histology, no. (%)
Adenocarcinoma 22 (100) 20 (90.9) 0.351
Giant cell carcinoma 0 (0) 1 (4.5)
Adenosquamous carcinoma 0 (0) 1 (4.5)
Grading
2 14 (63.6) 14 (66.7) 0.835
3 8 (36.4) 7 (33.3)
Pancreatic tumor location, no. (%)
Head 12 (50) 12 (48.0) 0.946
Body 4 (16.7) 3 (12.0)
Tail 7 (29.2) 9 (36.0)
Papilla Vateri 1 (4.2) 1 (4.0)
T-stage
2 1 (4.8) 2 (8.3) 0.063
3 16 (76.2) 10 (41.7)
4 4 (19) 12 (50.0)
Non-metastatic disease, no. (%) 0 (0) 6 (24.0)
Metastatic disease, no. (%) 15 (62.5) 13 (52.0)
Metastatic sites, no. (%)
Liver 9 (60.0) 6 (46.2) 0.466
Liver/peritoneum 4 (26.7) 4 (30.7)
Lung 2 (13.3) 2 (15.4)
Liver/lung 3 (20.0) 1 (7.7)
Relapsed disease, no (%) 9 (37.5) 6 (24.0) 0.629
Locoregional 1 (11.1) 0 (0.0)
Visceral (liver, lung, periteonal) 4 (44.4) 3 (50.0)
Locoregional/visceral 4 (44.4) 3 (50.0)
BMI, body mass index. Bold text, statistically significant.
advanced pancreatic cancer and a good performance status (8). grade 3 and 4 toxicities (7,8). Understanding the features that
However, it was reported that a considerable percentage of determine response or resistance to this chemotherapy regimen
patients, up to 50%, treated with FOLFIRINOX experienced could permit the selection of the most suitable patients for
INTERNATIONAL JOURNAL OF ONCOLOGY 44: 319-326, 2014 323
Figure 1. Consort diagram of the study population.
Figure 2. Kaplan-Meier survival estimates of (A) progression-free survival and (B) overall survival of female patients (solid line) and male patients (dotted line).
treatment with FOLFIRINOX. Thus, in our study, we evalu- The objective response rate, defined as the percentage of
ated clinical and histological markers and their associations patients with CR and PR, was slightly higher (55.1%) in our
with response to FOLFIRINOX. overall study population compared to the 32% reported by
324 HOHLA et al: PREDICTIVE MARKERS FOR THERAPY RESPONSE TO FOLFIRINOX
Table III. Response rates in all patients and in patients allo- Table IV. Efficacy of FOLFIRINOX in primary and relapsed
cated according to gender (female vs. male). pancreatic carcinomas.
Variable Total (n=49) Primary treatment All patients (n=34) P-value
Response, no. (%) Response, no. (%)
CR 0 (0) PR+SD 24 (70.6)
PR 27 (55.1) PD 10 (29.4)
SD 7 (14.3)
PD 15 (30.6) Female (n=15) Male (n=19)
Rate of disease
Response, no. (%)
control (PR + SD)
PR+SD 15 (100) 9 (47.4) 0.001
No. (%) 34 (69.4)
PD 0 (0) 10 (52.6)
Variable Female (n=24) Male (n=25) P-value
Treatment relapsed
stage All patients (n=15) P-value
Response, no. (%)
PR 18 (75) 9 (36) 0.004
Response, no. (%)
SD 4 (16.7) 3 (12)
PR+SD 10 (66.7)
PD 2 (8.3) 15 (52)
PD 5 (33.3)
Rate of disease
control (PR + SD) Female (n=9) Male (n=6)
No. (%) 22 (91.7) 12 (48) 0.001
Response, no. (%)
CR, complete remission; PR, partial remission; SD, stable disease;
PR+SD 7 (77.8) 3 (50) 0.064
PD, progressive disease.
PD 2 (22.2) 3 (50)
CR, complete remission; PR, partial remission; SD, stable disease;
PD, progressive disease.
Conroy et al (8). This might be explained by the fact that
in our highly selected study population all patients (100%)
exhibited an ECOG performance status (PS) 0 whereas the
majority (61%) of patients in the historical group of Conroy
et al had an ECOG PS 1. Higher response rates of 45% The percentage of patients with SD reported by Conroy et al
compared to the historical data of Conroy et al were also was higher compared to our study population (39 vs.
obtained in another retrospective analysis performed by 14.3%). Therefore, a similar disease control rate, defined as
Gunturu et al (12). This study population also consisted of percentage of patients with CR, PR or SD, could be seen in
a higher percentage of patients (69%) with an ECOG PS 0. our study compared to historical data (69.4 vs. 70%) (8).
Table V. Median progression-free and overall survival.
Progression-free survival Overall survival
median, months (95% CI) median, months (95% CI)
Overall study population
All patients (n=49) 3.5 (2.7-4.3) 13 (9.4-16.6)
Female (n=25) 5.0 (3.6-6.4) 15 (6.5-23.5)
Male (n=24) 3.0 (2.4-3.6) 12 (9.7-14.3)
Primary treatment
All patients (n=34) 4.0 (2.7-5.3) 11 (9.9-12.0)
Female (n=15) 5.0 (3.5-6.5) 11 (9.3-12.7)
Male (n=19) 3.0 (2.3-3.7) 11 (1.3-8.4)
Treatment relapsed stage
All patients (n=15) 3.0 (1.6-4.4) 21 (19.1-22.9)
Female (n=9) 3.5 (2.0-5.0) 22 (19.1-24.9)
Male (n=6) 2.0 (n.a.) 20 (12.8-27.2)
n.a., not applicable.
INTERNATIONAL JOURNAL OF ONCOLOGY 44: 319-326, 2014 325
Table VI. Clinicopathological characteristics and their associa- between the female and male group in our study. CA19.9 is
tion with response to treatment with FOLFIRINOX. the most extensively studied and validated biomarker for the
diagnosis of pancreatic cancer (13). Despite its limitations as
Variable PR PD P-value false negative results in sialyl Lewis negative individuals and
false positive elevation in the presence of obstructive jaun-
Ki-67 expression (%)
dice CA19.9 serum levels as well as a reduction in CA19.9
Median 25 17.5 0.328
levels during treatment have prognostic and predictive value
Range 1-80 1-70
(13). It has been reported that patients with pretreatment
Mutant p53 levels lower than median showed a better tumor response to
expression (%) neoadjuvant radiochemotherapy with 5-FU or adjuvant CTX
Median 20 5.5 0.422 with gemcitabine (14,15). There are no data so far regarding
Range 0-100 1-90 the predictive value of pretreatment levels of CA19.9 and
Level of response to CTX with FOLFIRINOX. In our patients
carbohydrate antigen 19.9 serum levels of CA19.9 (p=0.037) and CEA (0.05) were
Median 1612 1322 0.529 significantly higher in female patients compared to males
Range 1-140241 0-32266 (Table II). There was a tendency of higher serum levels of
CA19.9 (median 1,612 vs. 1,322 U/ml) in tumors of objective
Level of carcino-
responders (PR) compared to patients with PD (Table V).
embroygenic antigen
However, the difference did not reach significance probably
Median 7 7.45 0.752
because of the limited sample size. While an association of
Range 2-363 2-306
response to CTX and the rate of Ki67 in breast cancer as
Age, years
well some gastrointestinal cancers has been reported, data in
Median 61 63 0.783
pancreatic cancer for Ki67 as a potential predictive marker
Range 42-73 46-69
for response CTX cancer are lacking (16-19). The prolif-
Body mass index eration rate of tumor cells as defined by Ki67 was higher
Median 21.8 23 0.312 in responders vs. non-responders (median 25.0 vs. 17.5%
Range 17.2-30.7 18.2-30.7 positive cells) in our patients. In univariate analysis of our
cohort, CA19.9 serum levels were significantly associated
PR, partial remission; PD, progressive disease. with the expression of Ki67 in univariate analysis (p=0.017,
r=0.39, data not shown).
Despite its central role in the control of apoptosis, senes-
cence and cell cycle arrest, the tumor suppressor protein p53
When RRs were assessed according to gender a highly remains an enigma for its possible role in predicting response
significant difference in response to FOLFIRINOX could to chemotherapy in cancer patients. Mutant p53 proteins
be seen between the female and male treatment groups. As generally have an increased stability and accumulate in the
shown in Table III, there was a significant higher percentage nucleus of tumor cells and may be detectable by immunohis-
of female patients with PR (75%) compared to males (36%) tochemistry. It is believed that this is a consequence of the
(p=0.004) leading to a significantly (p=0.001) higher inactive p53 mutant protein not inducing the MDM2 protein
disease control rate in female patients (91.7 vs. 48.0%). To required to target its own degradation (20). The status of p53 is
our knowledge, this is the first study reporting different associated with cancer cell resistance to various chemothera-
response rates to CTX according to gender in patients with peutics (21,22). Wild-type p53 is thought to render tumors
pancreatic cancer. Although we could see a tendency towards more sensitive to treatment by the induction of apoptosis, and
a longer median PFS in female patients (5 months) compared p53 inactivation may lead to resistance to treatment. However,
to males (3 months) (p=0.099) significantly higher response because p53 is also responsible for prolonged cell cycle arrest
rates did not cause a significant difference in the median after chemotherapy-induced genetic damage, it is expected to
OS between female and male patients (15 vs. 12 months) facilitate DNA repair in the absence of an apoptotic response.
(p=0.200) (Table V, Fig. 2). This might be explained by the Therefore tumors that inactivate p53 might be less capable of
small sample size as well as the fact, that there was a higher DNA repair and more sensitive to a DNA damage-induced
number of locally advanced non-metastatic tumors in male mitotic catastrophe as reported in gastric cancer (23). In our
patients compared to females (6 vs. 0) (p=0.095) (Table II). cohort of patients p53 staining was increased in responders
Patients with locally advanced pancreatic tumors are known as compared to non-responders (20.0 vs. 5.5% positive cells,
to have a longer median OS of 15.7 months than patients Table VI), although this difference was not statistically signif-
with metastatic pancreatic tumors (9.5 months) (7). Thus, icant. The role of p53 in predicting response to FOLFIRINOX
the higher number of locally advanced pancreatic tumors in pancreatic cancer patients will have to be studied in a larger
in male patients might have nullified the benefit of higher cohort of patients.
response rates in female patients. Retrospective analyses The results of our study indicate, that female gender could
should be viewed with caution and causes for the improved positively predict response to FOLFIRINOX in patients with
RR to FOLFIRINOX in the female study population remain advanced pancreatic cancer. The predictive value of serum
speculative. Demographic and baseline disease character- levels of CA19.9 and expression of p53 and Ki67 in advanced
istics were well-balanced and did not differ significantly pancreatic tumors require further substantiation.
326 HOHLA et al: PREDICTIVE MARKERS FOR THERAPY RESPONSE TO FOLFIRINOX
References 12. Gunturu KS, Yao X, Cong X, et al: FOLFIRINOX for locally
advanced and metastatic pancreatic cancer: single institution
retrospective review of efficacy and toxicity. Med Oncol 30:
1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012.
361, 2013.
CA Cancer J Clin 62: 10-29, 2012.
13. Ballehaninna UK and Chamberlain RS: The clinical utility of
2. Lefebvre AC, Maurel J, Boutreux S, et al: Pancreatic cancer:
serum CA 19-9 in the diagnosis, prognosis and management
incidence, treatment and survival trends - 1175 cases in
of pancreatic adenocarcinoma: An evidence based appraisal.
Calvados (France) from 1978 to 2002. Gastroenterol Clin Biol
J Gastrointest Oncol 3: 105-119, 2012.
33: 1045-1051, 2009.
14. Micke O, Bruns F, Kurowski R, et al: Predictive value of
3. Burris HA III, Moore MJ, Andersen J, et al: Improvements
carbohydrate antigen 19-9 in pancreatic cancer treated with
in survival and clinical benefit with gemcitabine as first-line
radiochemotherapy. Int J Radiat Oncol Biol Phys 57: 90-97,
therapy for patients with advanced pancreas cancer: a random-
2003.
ized trial. J Clin Oncol 15: 2403-2413, 1997.
15. Humphris JL, Chang DK, Johns AL, et al: The prognostic and
4. Di Marco M, Di Cicilia R, Macchini M, et al: Metastatic pancre-
predictive value of serum CA19.9 in pancreatic cancer. Ann
atic cancer: is gemcitabine still the best standard treatment?
Oncol 23: 1713-1722, 2012.
(Review). Oncol Rep 23: 1183-1192, 2010.
16. Fasching PA, Heusinger K, Haeberle L, et al: Ki67, chemo-
5. Cunningham D, Chau I, Stocken DD, et al: Phase III random-
therapy response, and prognosis in breast cancer patients
ized comparison of gemcitabine versus gemcitabine plus
receiving neoadjuvant treatment. BMC Cancer 11: 486, 2011.
capecitabine in patients with advanced pancreatic cancer. J Clin
17. Zhang GC, Qian XK, Guo ZB, et al: Pre-treatment hormonal
Oncol 27: 5513-5518, 2009.
receptor status and Ki67 index predict pathologic complete
6. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus
response to neoadjuvant trastuzumab/taxanes but not disease-
gemcitabine compared with gemcitabine alone in patients with
free survival in HER2-positive breast cancer patients. Med
advanced pancreatic cancer: a phase III trial of the National
Oncol 29: 3222-3231, 2012.
Cancer Institute of Canada Clinical Trials Group. J Clin Oncol
18. Carlomagno C, Pepe S, D'Armiento FP, et al: Predictive factors
25: 1960-1966, 2007.
of complete response to neoadjuvant chemoradiotherapy in
7. Conroy T, Paillot B, Francois E, et al: Irinotecan plus oxaliplatin
patients with rectal cancer. Oncology 78: 369-375, 2010.
and leucovorin-modulated fluorouracil in advanced pancre-
19. Ressiot E, Dahan L, Liprandi A, et al: Predictive factors of
atic cancer - a Groupe Tumeurs Digestives of the Federation
the response to chemoradiotherapy in esophageal cancer.
Nationale des Centres de Lutte Contre le Cancer study. J Clin
Gastroenterol Clin Biol 32: 567-577, 2008.
Oncol 23: 1228-1236, 2005.
20. Soussi T: p53 alterations in human cancer: more questions than
8. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus
answers. Oncogene 26: 2145-2156, 2007.
gemcitabine for metastatic pancreatic cancer. N Engl J Med
21. Sax JK and El-Deiry WS: p53 downstream targets and chemo-
364: 1817-1825, 2011.
sensitivity. Cell Death Differ 10: 413-417, 2003.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines
22. Bertheau P, Espie M, Turpin E, et al: TP53 status and response
to evaluate the response to treatment in solid tumors. European
to chemotherapy in breast cancer. Pathobiology 75: 132-139,
Organization for Research and Treatment of Cancer, National
2008.
Cancer Institute of the United States, National Cancer Institute
23. Bataille F, Rummele P, Dietmaier W, et al: Alterations in p53
of Canada. J Natl Cancer Inst 92: 205-216, 2000.
predict response to preoperative high dose chemotherapy in
10. Dowsett M, Nielsen TO, A'Hern R, et al: Assessment of Ki67
patients with gastric cancer. Mol Pathol 56: 286-292, 2003.
in breast cancer: recommendations from the International
Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:
1656-1664, 2011.
11. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F and
Capocaccia R: EUROCARE-4. Survival of cancer patients
diagnosed in 1995-1999. Results and commentary. Eur J Cancer
45: 931-991, 2009.
